Should I Buy CMPS? CMPS 2026 Analysis

Should You Buy Compass Pathways PLC (CMPS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

6.190

1 Day change

8.41%

52 Week Range

8.200

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: today’s sharp selloff (-7.74%) is being driven by a fresh, high-impact policy/regulatory headline that can keep pressure on the stock.
Risk/reward is unattractive near-term: price is below the pivot (6.907) and sitting close to support (S2 ~6.267), meaning downside can accelerate if support breaks.
No help from Intellectia signals today: Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Net: avoid/bail now; revisit only after the regulatory overhang clears and price reclaims key levels (above ~6.91–7.30).

Technical Analysis

Trend/price action: strong bearish impulse today (regular session -7.74%) following negative news; momentum favors sellers.
MACD: histogram at -0.112 (below zero) and only “negatively contracting” — still bearish, with no confirmed reversal yet.
RSI(6): 30.49 (near oversold), which can produce a short bounce, but it’s not a reliable buy signal by itself in a news-driven downdraft.
Moving averages: converging (no clear bullish alignment); suggests lack of established uptrend.
Key levels:
- Resistance/pivot overhead: Pivot 6.907, then R1 7.303 (needs reclaim to improve structure).
- Support: S1 6.512 already under pressure; S2 6.267 is the line in the sand.
Pattern-based forward odds (provided): modest edge to downside over the next week (-2.77% expected), not supportive of an immediate buy.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning vs flow is mixed:
- Open interest P/C = 0.26 (call-heavy OI; longer-dated positioning looks optimistic).
- Volume P/C = 1.86 (today’s flow skewed put-heavy; near-term sentiment turned defensive).
Activity/volatility:
- Today’s options volume is elevated (today vs 30D avg ~140%), indicating heightened event-driven trading.
- IV is very high (~87%), but IV percentile ~28 and IV rank ~15 suggest it’s not at the top of its own recent range; still, options are pricey in absolute terms.
Takeaway: despite bullish OI, today’s put-heavy volume aligns with the negative news shock and near-term caution.

Technical Summary

Sell

Buy

Positive Catalysts

and RBC raised PT to $21 while reiterating Outperform (Jan 2026).
scheduled for 2026-02-26 pre-market (can reset sentiment if guidance/updates surprise positively).

Neutral/Negative Catalysts

and pressing supports (6.512 / 6.267).
on elevated activity.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: effectively $0 (no growth base; still pre-commercial).
Profitability/cash burn trend: Net income at -$137.7M (reported as “up” 257.69% YoY, which implies losses worsened materially YoY given the negative sign).
EPS: -1.44 (reported “up” 157.14% YoY, also implying deterioration given the negative sign).
Bottom line: fundamentals remain development-stage with meaningful losses; the stock is highly sensitive to regulatory/clinical timeline changes.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend is bullish:
- 2026-01-23: RBC raised PT to $21 (from $16), kept Outperform.
- 2025-12-09: Oppenheimer upgraded to Outperform (from Perform), PT $15.
Wall Street pro view (pros): high conviction in COMP360 leadership potential; large perceived market opportunity if FDA approval path succeeds.
Wall Street con view (cons): timeline/regulatory fragility and execution risk are decisive; today’s fast-track block highlights how quickly the thesis can be delayed.
Note: one item in the feed references “Compass Therapeutics” (a different company) — not directly applicable to CMPS.

9 Analyst Rating

Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is 17.67 USD with a low forecast of 8 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 5.710

Low

Averages

17.67

High

Current: 5.710

Low

Averages

17.67

High

RBC Capital

Leonid Timashev

Outperform

maintain

$16 -> $21

AI Analysis

2026-01-23

Reason

RBC Capital

Leonid Timashev

Price Target

$16 -> $21

AI Analysis

2026-01-23

maintain

Outperform

Reason

RBC Capital analyst Leonid Timashev raised the firm's price target on Compass Pathways to $21 from $16 and keeps an Outperform rating on the shares. Following the firm's Psychedelics Symposium, the firm is introducing a few changes to its CMPS model to better reflect the attitudes of key opinion leaders and companies on pricing, as well as the barriers to generic entry in the emerging innovative psychedelic therapy landscape, the analyst tells investors in a research note.

Oppenheimer

Perform -> Outperform

upgrade

$15

2025-12-09

Reason

Oppenheimer

Price Target

$15

2025-12-09

upgrade

Perform -> Outperform

Reason

Oppenheimer upgraded Compass Pathways to Outperform from Perform with a $15 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CMPS

Unlock Now

CMPS Should I Buy

CMPS Should I Buy

Should You Buy Compass Pathways PLC (CMPS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch